Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin’s lymphoma

A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).

(2017) V. A. Morrison et al.   JOURNAL OF CLINICAL ONCOLOGY

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

(2011) J. W. Friedberg et al.   BLOOD

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study

(2011) Julie E. Chang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non-Hodgkin Lymphoma

(2011) J. Gerecitano et al.   CLINICAL CANCER RESEARCH

Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma

(2011) W. Lamm et al.   HAEMATOLOGICA

Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

(2011) Nathan Fowler et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group

(2011) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

(2011) Bertrand Coiffier et al.   LANCET ONCOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

(2010) Jia Ruan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

(2009) Paul M. Barr et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase II study of bortezomib in patients with MALT lymphoma

(2009) M. Troch et al.   HAEMATOLOGICA

Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma

(2009) Sven de Vos et al.   JOURNAL OF CLINICAL ONCOLOGY

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

(2009) Massimo Federico et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of a new prognostic index for patients with chronic lymphocytic leukemia

(2008) Tait D. Shanafelt et al.   CANCER

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

(2008) Robert Marcus et al.   JOURNAL OF CLINICAL ONCOLOGY